Last reviewed · How we verify
T3011
At a glance
| Generic name | T3011 |
|---|---|
| Sponsor | ImmVira Pharma Co. Ltd |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of T3011 in Subjects With Advanced Melanoma (PHASE1, PHASE2)
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC (PHASE2)
- A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients (PHASE1)
- Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer (PHASE1)
- T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T3011 CI brief — competitive landscape report
- T3011 updates RSS · CI watch RSS
- ImmVira Pharma Co. Ltd portfolio CI